NYSE
$39.41▼ 0.03%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $45.89BShares out 11.600M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
27- 10.8After-hours26.10.09 05:013Ownership#●●●
TEVA PHARMACEUTICAL INDUSTRIES LTD
Teva Pharmaceutical Industries Ltd has filed a Form 3, disclosing the initial statement of beneficial ownership for insider Dov Bergwerk. This filing serves as the official record of the reporting person's equity holdings in the company.…more
$39.41-0.03%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 9.22After-hours26.09.23 06:014Ownership
TEVA PHARMACEUTICAL INDUSTRIES LTD
Teva Pharmaceutical insider Brian Savage reported a change in beneficial ownership of securities effective September 18, 2026. This filing serves as a standard Form 4 disclosure regarding executive stock holdings.…more
$39.41-0.03%vs prev closeView filingShare - 9.22After-hours26.09.23 05:214Ownership
TEVA PHARMACEUTICAL INDUSTRIES LTD
Insider Roberto Mignone reported a change in beneficial ownership of Teva Pharmaceutical Industries Ltd securities as of September 19, 2026. This filing serves as a standard disclosure of insider transaction activity and does not involve material changes to the company's capital structure or financial position.…more
$39.41-0.03%vs prev closeView filingShare
26 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 5d agoPre-market26.10.20 21:02#●●●#●●●#●●●
Teva and Sanofi Report Positive Phase 2b Data for Duvakitug
Teva and Sanofi announced that their investigational drug duvakitug maintained clinical efficacy in patients with ulcerative colitis and Crohn's disease through 44 weeks of a phase 2b study. The data demonstrated consistent improvements in clinical remission and endoscopic response, supporting the drug's potential as a treatment for inflammatory bowel disease.…more
$39.41-0.03%vs prev closeDetected5m · 30m · 60m · Next dayPLUSShareBenzinga
- 10.12After-hours26.10.13 06:45
●●●●●●●● ●●●●● ●●●●●●
Teva announced it will host an R&D Day in New York on November 11 to discuss its pipeline and growth strategy for the next five years. The event will focus on the company's transformation into an innovative biopharma firm and will be available via live webcast.…more
$39.41-0.03%vs prev close - 10.9Regular26.10.10 01:28
●●●●●●●● ●●●●● ●●●●●●
Teva Pharmaceutical has secured FDA approval for Weltruza, a once-monthly injectable treatment for schizophrenia. The drug demonstrated significant symptom reduction in Phase 3 trials and is expected to strengthen the company's growth strategy.…more
$39.41-0.03%vs prev closeShareBenzinga
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report